Breast Cancer

The efficacy of combination therapy with a checkpoint inhibitor and chemotherapy has been proved in the triple-negative breast cancer space, and the additive and early toxicity may be worth the survival benefit, according to Lisa A. Carey, MD.

Hope S. Rugo, MD, discusses CDK4/6 inhibition in HR-positive breast cancer, mechanisms of resistance to these drugs, and other potential pathway blockades.

Michelle E. Melisko, MD, discusses the clinical implications of the TAILORx and MINDACT studies.

In a presentation during an OncLive® State of the Science Summit™, Melanie Majure, MD, discussed the duration of endocrine-directed therapy for estrogen receptor–positive breast cancer.

Peter Schmid, MD, PhD, shares the results of IMpassion130 and discussed his thoughts on the future of immunotherapy in breast cancer.

Joseph A. Sparano, MD, discusses the potential for liquid biopsy and the ongoing challenge of improving survival for patients with metastatic breast cancer.

Peter Schmid, MD, PhD, lead at the Centre for Experimental Cancer Medicine, Barts Cancer Institute, discusses findings from the IMpassion130 trial in triple-negative breast cancer (TNBC).

More than half of patients with advanced solid tumors associated with NTRK gene fusions responded to treatment with the small-molecule inhibitor entrectinib, an integrated analysis of 3 clinical trials showed.

Fabrice André, MD, PhD, professor, Department of Medical Oncology, Institut Gustave Roussy, discusses the impact of the SOLAR-1 findings in breast cancer at the 2018 ESMO Congress.

The addition of the PI3K inhibitor alpelisib to fulvestrant nearly doubled median progression-free survival compared with the endocrine therapy alone in patients with HR-positive/HER2-negative advanced breast cancer who have a PIK3CA mutation.

The combination of palbociclib plus fulvestrant led to a clinically meaningful benefit in overall survival in patients with hormone receptor–positive, HER2-negative advanced breast cancer who had progressed or relapsed on prior endocrine therapy.

Massimo Cristofanilli, MD, professor of medicine (hematology and oncology), Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, discusses survival findings from the PALOMA-3 trial in hormone receptor-positive, HER2-negative breast cancer.

The addition of atezolizumab to nab-paclitaxel reduced the risk of progression or death by 38% compared with nab-paclitaxel alone in patients with PD-L1–positive metastatic triple-negative breast cancer.

William J. Gradishar, MD, chief of hematology and oncology, Department of Medicine, Betsy Bramsen Professorship of Breast Oncology, professor of medicine (hematology and oncology), Northwestern University's Feinberg School of Medicine, discusses the rise of personalized treatment in breast cancer.

Tari King, MD, FACS, chief of Breast Surgery, Dana-Farber Cancer Institute, Brigham Women’s Cancer Center, discusses surgical approaches in breast cancer.

Denise A. Yardley, MD, senior investigator of breast cancer research, Sarah Cannon Research Institute, discusses the FDA approval of talazoparib (Talzenna) for the treatment of patients with germline BRCA mutation–positive, HER2-negative locally advanced or metastatic breast cancer